Insight & Intelligence

More »


More »

For full access to this article login to GEN Select now.

April 15, 2014 (Vol. 34, No. 8)

Membrane Protein Solutions for Antibody Discovery

Generation of Monoclonal Antibodies against Difficult Membrane Protein Targets

  • Biologics are the fastest growing class of pharmaceuticals, with hundreds of monoclonal antibodies (mAbs) currently being developed and over thirty mAbs approved for the treatment of conditions ranging from cancer to autoimmune and inflammatory diseases. In the case of membrane protein targets, mAbs can avoid many of the pitfalls ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.